SCHEMBL7812397

SCHEMBL7812397

COc1cc2c(cc1C)n[c]n2C

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 6/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
G6PD P11413 1/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP19A1 P11511 2/20 0.33
TAAR1 Q96RJ0 1/20 0.32
S100B P04271 1/20 0.31
LCK P06239 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7814717 0.93 LMNA (0.33) NQO2LMNANPC1RAB9AMAPT
SCHEMBL5982809 0.87 FGFR1 (0.39) NQO2LMNAPOLBMEN1KMT2A
SCHEMBL5981558 0.81 KDM4E (0.40) NQO2LMNANPC1RAB9AMAPT
SCHEMBL7814442 0.78 MEN1 (0.41) LMNAMEN1KMT2ATSHRL3MBTL1
SCHEMBL7815203 0.77 CD44 (0.34) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3652546 0.70 TDP1 (0.44) NQO2LMNANPC1RAB9AMAPT
SCHEMBL7815337 0.70 ALDH1A1 (0.43) NQO2LMNANPC1RAB9AMAPT
SCHEMBL5982758 0.70 PTPN1 (0.40) LMNANPC1RAB9AMAPTPOLB
SCHEMBL7815084 0.68 EGLN1 (0.35) LMNAMAPTMEN1KMT2ATSHR
SCHEMBL25682666 0.68 SMN1; SMN2 (0.44) NQO2LMNANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed